Not checked for notices yet.

Persistent but dysfunctional mucosal SARS-CoV-2-specific IgA and low lung IL-1β associate with COVID-19 fatal outcome: A cross-sectional analysis

Maria Julia Ruiz, Maria Julia Ruiz, Maria Julia Ruiz and 34 more

Frontiers in Immunology · 2022

doi:10.3389/fimmu.2022.842468

References 87

1.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
2.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
3.
Coronavirus Cell Entry Occurs through the Endo-/Lysosomal Pathway in a Proteolysis-Dependent Manner · 2014
Corrected
4.
Multi-Faceted Functions of Secretory IgA at Mucosal Surfaces · 2013
No notice
5.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
6.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
7.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
8.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
9.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
10.
Secretory IgA: Designed for Anti-Microbial Defense · 2013
No notice
11.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
12.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
13.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
14.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
15.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
16.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
17.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
18.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
19.
The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2 · 2020
No notice
20.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
21.
Serological and molecular findings during SARS-CoV-2 infection: the first case study in Finland, January to February 2020 · 2020
No notice
22.
The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak – an update on the status · 2020
No notice
23.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
24.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
25.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
26.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
27.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
28.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
29.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
30.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
31.
Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model · 2020
No notice
32.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
33.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
34.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
35.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
36.
Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19 · 2020
No notice
37.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
38.
A longitudinal study of SARS-CoV-2-infected patients reveals a high correlation between neutralizing antibodies and COVID-19 severity · 2021
No notice
39.
SARS-CoV-2 seroprevalence and neutralizing activity in donor and patient blood · 2020
No notice
40.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library

All 87 references

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.